Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

IT, healthcare help put up strong show
Tue, 19 Feb Closing

In what could be termed as a strong turnaround, indices in the Indian equity market sprung to life during the closing stages, enabling the markets to close sufficiently higher for the day. Thus, while BSE Sensex edged higher by around 135 points (up 0.7%), gains on the NSE-Nifty came in at about 42 points. BSE Mid Cap and BSE Small Cap indices performed even better, logging in gains of around 1% each. Nearly three stocks gained for every one that closed the day in the red on the Sensex

While Asian stocks closed mixed today, Europe is trading mostly in the green currently. The rupee was placed at Rs 54.3 to the dollar at the time of writing.

Just as it was being felt that today would be another lacklustre day, the indices surprised everyone with strong buying towards the closing hour. It was buoyancy in heavyweights like Oil and Natural Gas Corporation (ONGC), Infosys and ICICI Bank that really aided the proceedings. That said, the buying was actually broad based with very few Sensex stocks closing in the red.

Software giant Infosys continued with its good recent run on the bourses today as it edged higher by 1%. As per reports, the company has become the first Indian company that will be admitted to trading on NYSE Euronext's London and Paris markets from tomorrow, Feb 20, 2013. This listing will help UK, French and other European investors to have direct access to Infosys ADS and allows investors from these countries to benefit from the Indian IT story.

GSK Pharma has declared Dec 2012, results. The topline grew by 15% YoY during the quarter, this was largely helped by growth in its core business which grew by 16% for the said period. The operating margins declined by 2.1% due to increase in operating expenses and decline in operating income. The bottom line increased by 1.4% YoY during 3QCY13, due to exceptional loss, rationalizing initiatives at manufacturing sites and actuarial loss on employee benefits. Company is incurring these losses since last few months. Adjusting for these exceptional losses, PAT grew by around 10% for the quarter. The stock closed marginally higher on the bourses today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT, healthcare help put up strong show". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.